Outlook Therapeutics, Inc. income statement OTLK

Annual Quarterly

In fiscal 2025, which ended Sep 30, 2025, Outlook Therapeutics, Inc. reported revenue of $1.4 million. It recorded a net loss of $62.4 million. The operating loss came to $67.1 million, an operating margin of -4744.3%. Diluted earnings per share were -$1.79. Across the 5 fiscal years shown, revenue shrank from $3.0 million in fiscal 2016 to $1.4 million in fiscal 2025, about 17.0% a year.

USD in millions, except per-share amounts and margins. The percent under a figure is the change from the year before.

Line	FY 2025 Sep 30, 2025	FY 2024 Sep 30, 2024	FY 2023 Sep 30, 2023	FY 2022 Sep 30, 2022	FY 2021 Sep 30, 2021	FY 2020 Sep 30, 2020	FY 2019 Sep 30, 2019	FY 2018 Sep 30, 2018	FY 2017 Sep 30, 2017	FY 2016 Sep 30, 2016
Revenue	1	—	—	—	—	—	8 +163.8%	3 -19.0%	4 +27.9%	3
Cost of revenue	1	—	—	—	—	—	—	—	—	—
Gross profit	0	—	—	—	—	—	—	—	—	—
Research and development	27 -34.9%	42 +57.9%	26 -37.5%	42 +8.7%	39 +47.9%	26 +10.7%	24 +28.6%	19 -22.3%	24 -27.3%	33
Selling, general and administrative	40 +33.4%	30 +12.2%	27 +28.6%	21 +62.4%	13 +28.1%	10 +6.4%	9 -34.1%	14 -10.4%	16 -26.3%	22
Operating expenses	67	—	—	—	—	—	—	—	—	—
Operating income	-67 +6.5%	-72 -35.0%	-53 +15.8%	-63 -21.9%	-52 -40.4%	-37 -1.5%	-36 -22.4%	-30 +17.4%	-36 +30.1%	-51
Pretax income	-64 +15.1%	-75 -27.8%	-59 +10.7%	-66 -24.2%	-53 -38.0%	-39 -1.5%	-38 -12.4%	-34 +12.0%	-38 +27.9%	-53
Income tax	-2 -55522.5%	0 +0.0%	0 +0.0%	0 +40.0%	0 +100.1%	-3 +4.1%	-3 +6.5%	-4 -827.5%	1 +386.9%	0
Net income	-62 +17.2%	-75 -27.8%	-59 +10.7%	-66 -24.2%	-53 -50.9%	-35 -2.1%	-35 -14.7%	-30 +22.5%	-39 +27.1%	-53
Basic EPS	-1.79 +55.9%	-4.06 +14.0%	-4.72 -1422.6%	-0.31 +11.4%	-0.35	—	—	-1.22 +26.9%	-1.67	—
Diluted EPS	-1.79 +55.9%	-4.06 +14.0%	-4.72 -1422.6%	-0.31 +11.4%	-0.35	—	—	-1.22 +32.2%	-1.80	—
Weighted average shares, basic	35 +87.6%	19 +48.3%	13 -94.1%	212 +38.9%	153	—	—	39 +64.3%	24	—
Weighted average shares, diluted	35 +87.6%	19 +48.3%	13 -94.1%	212 +38.9%	153	—	—	39 +64.1%	24	—
Other measures
Depreciation and amortization	0 +2.8%	0 +157.7%	0 -78.4%	0 -21.9%	0 -52.7%	1 -83.5%	3 +10.1%	3 +13.5%	3 +12.4%	2
EBITDA	-67 +6.5%	-72 -34.9%	-53 +15.6%	-63 -22.2%	-51 -41.8%	-36 -10.2%	-33 -23.9%	-27 +19.9%	-33 +32.2%	-49
Interest coverage	—	-22.71x	—	—	—	—	—	—	—	—
Margins
Gross margin	4.05%	—	—	—	—	—	—	—	—	—
Operating margin	-4,744.25%	—	—	—	—	—	-445.60%	-960.12%	-941.36%	-1,723.30%
Pretax margin	-4,526.01%	—	—	—	—	—	-465.68%	-1,092.78%	-1,006.10%	-1,785.46%
Profit margin	-4,416.22%	—	—	—	—	—	-423.81%	-974.62%	-1,019.26%	-1,788.91%
EBITDA margin	-4,735.97%	—	—	—	—	—	-404.33%	-861.20%	-870.73%	-1,642.95%

How these figures are calculated

Annual columns are full-year amounts from the annual report (Form 10-K, 20-F, or 40-F). If a company restates a year, the latest filed number is shown. USD in millions, except per-share amounts and margins. Weighted average shares are in millions. Interest expense and finance costs are positive costs. A negative amount on a gain (loss) or income (expense) line is a loss or an expense. EBITDA is operating income plus depreciation and amortization. Interest coverage is operating income divided by interest expense. More on our methodology.

New to this? Read How to Read an Income Statement, With a Real Example.

Company profile

Industry: Biological Products, (No Diagnostic Substances) (SIC 2836)
Listed as: OTLK (Nasdaq)
Fiscal year ends: September 30
Incorporated in: DE
Headquarters: Iselin, NJ
SEC filer status: Non-accelerated filer, Smaller reporting company
SEC CIK: 1649989
Former names: Oncobiologics, Inc. (until Nov 13, 2018)

Other Biological Products, (No Diagnostic Substances) companies

All 182 Biological Products, (No Diagnostic Substances) companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.